Shopping Cart 0
Cart Subtotal
USD 0

Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Oxford BioTherapeutics Ltd (OBT) is a clinical stage oncology company that develops antibody drug conjugates for the treatment of variety of cancers. The company's product pipelines currently includes T-cell based IO therapies including check point modulators; NK cell based IO therapies such as antibody dependent cell mediated toxicity (ADCCs); and Antibody drug conjugates (ADCs). Its therapeutic antibodies targets checkpoints restore anti-tumour immune function allowing the immune system to recognise and kill cancer cells. The company works in collaboration with companies for the development of component technologies to develop innovative ADCs. It operates through its offices in the UK and Switzerland. Oxford BioTherapeutics is headquartered in Abingdon, the UK.

Oxford BioTherapeutics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Calculus Capital Invests USD2.6 Million in Oxford BioTherapeutics 11

Partnerships 12

Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 12

Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 13

Invenra Enters into Agreement with Oxford BioTherapeutics 14

Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 15

Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 16

Licensing Agreements 17

Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 17

Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 18

Oxford BioTherapeutics Ltd-Key Competitors 19

Oxford BioTherapeutics Ltd-Key Employees 20

Oxford BioTherapeutics Ltd-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Corporate Communications 22

Jun 13, 2017: Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director 22

Feb 09, 2017: Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans 23

Product News 24

09/28/2017: Menarini Ricerche Attended the Brainstorming Meeting on CD38 and CD157 which was Held on September 21st-23rd 2017 at San Benedetto Po and Mantova (Italy) 24

03/01/2018: Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi M.D., Ph.D. 25

Clinical Trials 26

Sep 12, 2017: Oncology Research: New Opportunities for Menarini and OBT 26

Jun 21, 2017: Menarini Ricerche to Present the Most Recent Data About the Pre-Clinical Development of its Novel ABC Men1309/Obt076 at the 29th Pezcoller Symposium 27

Appendix 28

Methodology 28

About GlobalData 28

Contact Us 28

Disclaimer 28


List Of Figure

List of Figures

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oxford BioTherapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Calculus Capital Invests USD2.6 Million in Oxford BioTherapeutics 11

Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 12

Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 13

Invenra Enters into Agreement with Oxford BioTherapeutics 14

Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 15

Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 16

Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 17

Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 18

Oxford BioTherapeutics Ltd, Key Competitors 19

Oxford BioTherapeutics Ltd, Key Employees 20

Oxford BioTherapeutics Ltd, Subsidiaries 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Oxford BioTherapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.